Abstract：
BACKGROUND: The aim of this study was to compare the efficacy of mirabegron plus tamsulosin to tamsulosin monotherapy in terms of ureteral stent-related discomfort after ureteroscopic lithotripsy.
METHODS: A total of 102 patients undergoing ureteroscopic lithotripsy and silicone ureteral stent placement were enrolled in this study. Patients were randomized 1:1 to receive either tamsulosin 0.4 mg once daily or mirabegron 50 mg + tamsulosin 0.4 mg once daily during the stenting period. Before the operation, the IPSS, QOL, and pain score were collected. On the day of ureteral stent removal, the USSQ, analgesic usage amount was collected and recorded.
RESULTS: The median USSQ-body pain score in the tamsulosin group and tamsulosin + mirabegron group was 15 and 16, respectively (p = 0.530). The median analgesic usage in the two groups was 3 and 2, respectively (p = 0.170). The median USSQ-urinary symptoms, USSQ-general health, USSQ-work performance, USSQ-sexual matters, and USSQ-additional problems in the two groups were 26 and 26 (p = 0.194), 11 and 12 (p = 0.068), 12 and 13 (p = 0.105), 2 and 2 (p = 0.437), 9 and 9 (p = 0.533), respectively. The international patients used more analgesics than Chinese patients (6 vs. 1, p = 0.015).
CONCLUSIONS: Compared to tamsulosin alone, tamsulosin + mirabegron showed no additional benefit on the ureteral stent-related pain control after ureteroscopic lithotripsy and silicone stent placement. There was no significant difference on the analgesic usage and USSQ scores between the two groups. Chinese patients request fewer analgesics than international patients.
METHODS: A total of 102 patients undergoing ureteroscopic lithotripsy and silicone ureteral stent placement were enrolled in this study. Patients were randomized 1:1 to receive either tamsulosin 0.4 mg once daily or mirabegron 50 mg + tamsulosin 0.4 mg once daily during the stenting period. Before the operation, the IPSS, QOL, and pain score were collected. On the day of ureteral stent removal, the USSQ, analgesic usage amount was collected and recorded.
RESULTS: The median USSQ-body pain score in the tamsulosin group and tamsulosin + mirabegron group was 15 and 16, respectively (p = 0.530). The median analgesic usage in the two groups was 3 and 2, respectively (p = 0.170). The median USSQ-urinary symptoms, USSQ-general health, USSQ-work performance, USSQ-sexual matters, and USSQ-additional problems in the two groups were 26 and 26 (p = 0.194), 11 and 12 (p = 0.068), 12 and 13 (p = 0.105), 2 and 2 (p = 0.437), 9 and 9 (p = 0.533), respectively. The international patients used more analgesics than Chinese patients (6 vs. 1, p = 0.015).
CONCLUSIONS: Compared to tamsulosin alone, tamsulosin + mirabegron showed no additional benefit on the ureteral stent-related pain control after ureteroscopic lithotripsy and silicone stent placement. There was no significant difference on the analgesic usage and USSQ scores between the two groups. Chinese patients request fewer analgesics than international patients.
摘要：
背景：本研究的目的是比较米拉贝隆联合坦索罗辛与坦索罗辛单药治疗输尿管镜碎石术后输尿管支架相关不适的疗效。
方法：本研究共纳入102例接受输尿管镜碎石术和硅胶输尿管支架置入术的患者。患者以1：1的比例随机分配，在支架置入期间每天一次接受坦索罗辛0.4mg，每天一次或接受米拉贝隆50mg坦索罗辛0.4mg。手术前,IPSS,QOL,并收集疼痛评分。在移除输尿管支架的当天，USSQ,收集并记录镇痛使用量。
结果：坦索罗辛组和坦索罗辛+米拉贝隆组的中位USSQ-身体疼痛评分分别为15和16（p=0.530）。两组的镇痛药使用中位数分别为3和2（p=0.170）。USSQ-泌尿症状中位数，USSQ-一般健康，USSQ-工作性能,USSQ-性问题,两组的USSQ-额外问题分别为26和26（p=0.194），11和12（p=0.068），12和13（p=0.105），2和2（p=0.437），9和9（p=0.533），分别。国际患者使用的镇痛药比中国患者多（6vs.1，p=0.015）。
结论：与单用坦索罗辛相比，在输尿管镜碎石术和硅胶支架置入术后,坦索罗辛+米拉贝隆对输尿管支架相关疼痛控制无额外益处.两组止痛药用量和USSQ评分比较差异无统计学意义。中国患者比国际患者要求更少的镇痛药。
方法：本研究共纳入102例接受输尿管镜碎石术和硅胶输尿管支架置入术的患者。患者以1：1的比例随机分配，在支架置入期间每天一次接受坦索罗辛0.4mg，每天一次或接受米拉贝隆50mg坦索罗辛0.4mg。手术前,IPSS,QOL,并收集疼痛评分。在移除输尿管支架的当天，USSQ,收集并记录镇痛使用量。
结果：坦索罗辛组和坦索罗辛+米拉贝隆组的中位USSQ-身体疼痛评分分别为15和16（p=0.530）。两组的镇痛药使用中位数分别为3和2（p=0.170）。USSQ-泌尿症状中位数，USSQ-一般健康，USSQ-工作性能,USSQ-性问题,两组的USSQ-额外问题分别为26和26（p=0.194），11和12（p=0.068），12和13（p=0.105），2和2（p=0.437），9和9（p=0.533），分别。国际患者使用的镇痛药比中国患者多（6vs.1，p=0.015）。
结论：与单用坦索罗辛相比，在输尿管镜碎石术和硅胶支架置入术后,坦索罗辛+米拉贝隆对输尿管支架相关疼痛控制无额外益处.两组止痛药用量和USSQ评分比较差异无统计学意义。中国患者比国际患者要求更少的镇痛药。
